The Deal That Changed the Gene Editing Landscape
On July 14, 2025, Eli Lilly and Company announced that it had agreed to acquire Verve Therapeutics for approximately $1.3 billion in an all-cash transaction. The deal valued Verve at $10.50 per share plus a $3.00 contingent value right (CVR), representing a 113% premium over Verve's closing price the previous trading day. For a company whose stock had been battered by a clinical setback and whose market capitalization had dwindled to a fraction of its post-IPO peak, the acquisition was a lifeline. For Eli Lilly, it was something far more strategic: a declaration that one of the world's largest pharmaceutical companies believed the future of cardiovascular medicine would be written not in daily pills but in single-dose genetic cures.
The transaction closed in September 2025, and it immediately reshaped the conversation about gene editing's commercial trajectory. This was not a licensing agreement or a research collaboration. This was a full acquisition — Eli Lilly absorbing Verve's entire pipeline, its intellectual property, its team, and its manufacturing capabilities. And it landed in an area that no gene editing company had yet cracked: cardiovascular disease, the number one killer of human beings on the planet.
To understand why Lilly wrote this check, you have to understand three things: the staggering unmet need in cardiovascular disease, the promise and peril of Verve's base editing technology, and the broader strategic chess game playing out as big pharma races to secure positions in genetic medicine.
Cardiovascular Disease: The Trillion-Dollar Problem
Heart disease kills approximately 17.9 million people globally each year, accounting for roughly 32% of all deaths worldwide, according to the World Health Organization [1]. In the United States alone, cardiovascular disease claims about 695,000 lives annually — more than all forms of cancer combined [2]. The economic burden is equally staggering. The American Heart Association estimates that direct and indirect costs of cardiovascular disease in the U.S. exceed $400 billion per year, a figure projected to surpass $1 trillion by 2035 [3].
The pharmaceutical industry has not ignored this market. Statins — drugs that lower LDL cholesterol — generate tens of billions of dollars in annual revenue and have been one of the most commercially successful drug classes in history. More recently, injectable PCSK9 inhibitors like Repatha (evolocumab) and Praluent (alirocumab) have offered more powerful LDL reduction for patients who do not respond adequately to statins. Inclisiran (Leqvio), an RNA interference therapy from Novartis, arrives twice a year by injection and has been positioned as a more convenient alternative.
But all of these treatments share a fundamental limitation: they must be taken continuously. Stop the statin, and LDL cholesterol rises back to baseline. Skip the PCSK9 inhibitor injections, and the protective effect vanishes. Real-world adherence data is sobering. Studies have consistently shown that roughly 50% of patients prescribed statins discontinue them within the first year [4]. For PCSK9 inhibitors, adherence is even worse, owing to cost, injection burden, and side effects. Non-adherence to cardiovascular medications is estimated to cause approximately 125,000 preventable deaths per year in the U.S. alone [5].
This is the problem that Verve Therapeutics was built to solve. Not a better pill. Not a more convenient injection. A single treatment that permanently lowers LDL cholesterol by editing the genes responsible for its regulation — a one-and-done approach that would make adherence irrelevant.
For Eli Lilly, a company whose cardiovascular franchise had been relatively modest compared to its dominance in diabetes and obesity (Mounjaro and Zepbound), the Verve acquisition represented a chance to enter the cardiovascular space with a technology so differentiated that no competitor could replicate it quickly. In a world where GLP-1 receptor agonists are rapidly commoditizing and every major pharma company is developing its own version, Lilly was looking for the next frontier. Gene editing for heart disease was it.
Verve's Technology: Base Editing In Vivo
Verve Therapeutics was founded in 2018 by Sekar Kathiresan, a cardiologist-geneticist who had spent years at the Broad Institute and Massachusetts General Hospital studying the genetics of heart disease. Kathiresan's central insight came from a simple but profound observation in human genetics: people born with naturally occurring loss-of-function mutations in certain genes — particularly PCSK9 and ANGPTL3 — had dramatically lower LDL cholesterol levels and correspondingly lower rates of heart attack and cardiovascular death, with no apparent health consequences from carrying these mutations [6].
The implication was striking. If nature had already shown that turning off PCSK9 was safe and cardioprotective, why not do it deliberately?
Verve's approach used base editing, a refinement of CRISPR technology developed in the laboratory of David Liu at Harvard and the Broad Institute. Unlike traditional CRISPR-Cas9 editing, which creates double-strand breaks in DNA and relies on the cell's own repair machinery to introduce changes — a process that can be imprecise and sometimes introduces unwanted insertions or deletions — base editing makes precise single-letter changes to DNA without cutting both strands. A modified Cas9 protein is fused to a deaminase enzyme that chemically converts one DNA base to another (for example, converting a cytosine to a thymine). The result is a targeted, predictable edit with a substantially lower risk of off-target damage [7].
Verve's programs used this technology to introduce loss-of-function edits in two key targets:
VERVE-101 / VERVE-102: Targeting PCSK9. These programs aimed to introduce a single base change in the PCSK9 gene in liver cells, effectively silencing the gene and permanently reducing LDL cholesterol. The editing components — a base editor mRNA and a guide RNA — were delivered to the liver using lipid nanoparticles (LNPs), the same delivery technology used in the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines. This was a critical distinction from most gene editing therapies on the market, which require extracting cells from the patient, editing them in a laboratory, and infusing them back. Verve's approach was in vivo — the editing happens inside the patient's body, delivered by a single intravenous infusion.
VERVE-201: Targeting ANGPTL3. This second program targeted angiopoietin-like protein 3, another genetically validated target for lipid lowering. Loss-of-function mutations in ANGPTL3 are associated with a condition called familial combined hypolipidemia, characterized by very low levels of LDL cholesterol, triglycerides, and HDL cholesterol — and significantly reduced cardiovascular risk.
The elegance of the approach was undeniable. A single IV infusion, lasting roughly an hour, that permanently edits liver cells to stop producing a protein that drives LDL cholesterol. No daily pills. No biweekly injections. No adherence problem. If it worked, it would be the most significant advance in cardiovascular prevention since statins were introduced in the 1980s.
The VERVE-101 Setback
It did not go smoothly at first.
VERVE-101, Verve's lead candidate, used a base editor delivered via LNPs to target PCSK9 in patients with heterozygous familial hypercholesterolemia (HeFH), a genetic condition affecting roughly 1 in 250 people that causes dangerously elevated LDL cholesterol from birth. The Heart-1 clinical trial, a Phase 1b study conducted primarily in New Zealand and the United Kingdom, began dosing patients in 2022.
Early results were mixed. At lower doses, PCSK9 reduction was modest. At higher doses, there were signs of meaningful LDL reduction, but also concerning signals. In May 2024, Verve disclosed that a patient in the Heart-1 trial had died following treatment with VERVE-101. The patient, who had severe pre-existing cardiovascular disease, experienced a cardiac arrest approximately five weeks after dosing. Verve stated that an independent data safety monitoring board reviewed the case and concluded that the death was likely related to the patient's underlying condition rather than the study drug, but the damage to confidence was immediate [8].
Verve's stock, which had already been declining, cratered. Analysts downgraded the company. The clinical hold that followed — while standard procedure — amplified the perception that the program was in trouble. By late 2024, Verve had made the strategic decision to deprioritize VERVE-101 and shift its resources to its next-generation candidate, VERVE-102.
VERVE-102: The Candidate That Sealed the Deal
VERVE-102 represented a significant evolution of Verve's technology. While it targeted the same gene (PCSK9) and used the same base editing approach, it incorporated a next-generation lipid nanoparticle delivery system and an optimized guide RNA. The new LNP formulation was designed to improve liver targeting, reduce off-target editing, and lower the inflammatory response that had been observed with earlier LNP formulations.
The Heart-2 trial, a Phase 1b study of VERVE-102 in patients with HeFH, began enrolling patients in late 2024. By mid-2025, interim data had been presented that electrified the cardiovascular and gene editing communities. In the cohorts dosed at therapeutic levels, VERVE-102 demonstrated:
- PCSK9 protein reduction of 84-95% from baseline
- LDL cholesterol reduction of 53-69% from baseline
- No serious adverse events (SAEs) related to the study drug
- Durable editing confirmed at the six-month follow-up, with no evidence of waning efficacy
These numbers were remarkable. A 53-69% LDL reduction from a single dose placed VERVE-102 in the same efficacy range as PCSK9 inhibitors — but without the need for ongoing treatment. The safety profile was clean, addressing the most critical question that had haunted the program since the VERVE-101 patient death [9].
For Eli Lilly, the VERVE-102 data resolved the central uncertainty. The base editing technology worked in humans. The delivery system could reach the liver efficiently. The LDL reduction was clinically meaningful. And the safety profile — at least in the early data — was acceptable. The question was no longer whether in vivo base editing was feasible; it was who would own it.
Inside the Deal Terms
The structure of Lilly's acquisition reflected both confidence in the technology and acknowledgment of the remaining clinical risk.
The $10.50 per share cash component represented the guaranteed payment to Verve shareholders. At the time of the announcement, Verve's stock was trading at approximately $4.93 per share, making the cash component alone a 113% premium.
The $3.00 CVR (contingent value right) added an additional potential payout, but it was contingent on a specific milestone: the initiation of a Phase 3 clinical trial for any Verve pipeline candidate within 10 years of the deal closing. This structure was notable for its long timeline — Lilly was essentially giving itself a decade to advance the programs through the remaining clinical development, recognizing that gene editing for cardiovascular disease was still in early clinical stages.
The CVR also included the transfer of certain rights that Verve had previously negotiated with Beam Therapeutics, the base editing platform company founded by David Liu. Verve had an exclusive license from Beam for the use of base editing technology in cardiovascular disease, and the acquisition included Lilly acquiring the opt-in rights that Beam held over certain Verve programs. This gave Lilly clean ownership of the cardiovascular base editing pipeline without ongoing obligations to Beam — a significant simplification of the intellectual property landscape [10].
The total deal value of approximately $1.3 billion (including the CVR) was modest by big pharma M&A standards — Lilly's market capitalization at the time exceeded $800 billion. But the strategic value extended far beyond the dollar figure. Lilly was not just buying a pipeline; it was buying a platform for in vivo gene editing in a therapeutic area that no other major pharma company had yet claimed.
The Big Pharma Gene Editing Land Grab
Lilly's acquisition of Verve did not happen in a vacuum. It was part of a broader pattern of major pharmaceutical companies moving aggressively to secure gene editing capabilities — a trend that accelerated dramatically in 2024 and 2025.
In March 2025, Pfizer announced a partnership with Beam Therapeutics worth up to $300 million upfront, with total potential payments exceeding $1 billion. The deal gave Pfizer access to Beam's base editing platform for up to five targets across multiple therapeutic areas, including liver-directed programs. Pfizer had been signaling interest in genetic medicines for years, and the Beam deal was its largest commitment to the space [11].
Sanofi took a different approach, partnering with Scribe Therapeutics, a CRISPR startup co-founded by Jennifer Doudna (who shared the 2020 Nobel Prize in Chemistry for her role in developing CRISPR). Sanofi's deal, also announced in 2025, focused on next-generation CRISPR editing approaches that Scribe had developed to improve editing efficiency and reduce off-target effects [12].
Novo Nordisk, fresh off its GLP-1 dominance, invested in gene editing capabilities through a combination of internal R&D and strategic investments, recognizing that the same metabolic disease patients it was treating with semaglutide might one day be candidates for genetic cures.
The pattern was unmistakable. After years of watching from the sidelines while smaller biotech companies pioneered gene editing in rare diseases and oncology, big pharma was moving in — and it was moving in with checkbooks open. The rationale was straightforward: the early clinical data had reached a point where the technology was de-risked enough for large companies to invest, but still early enough that strategic acquisitions and partnerships could be done at reasonable valuations.
For investors, this land grab validated a thesis that had been circulating in biotech venture circles for years: gene editing companies would ultimately be acquired by big pharma, not build into standalone commercial enterprises. The capital requirements for late-stage clinical development and global commercial launch in major disease areas like cardiovascular disease were simply too large for mid-cap biotechs to shoulder alone.
Impact on Beam Therapeutics
The Lilly-Verve acquisition had significant ripple effects for Beam Therapeutics, the Cambridge-based company that had developed the base editing technology underlying Verve's programs. Beam had been founded in 2017 by David Liu, Feng Zhang, and J. Keith Joung, and had positioned itself as the platform company for base editing — licensing its technology to partners while also developing its own pipeline of base editing therapies, primarily in hematology and oncology.
Beam's relationship with Verve was complex. Verve had an exclusive license from Beam for cardiovascular applications of base editing, and Beam held certain opt-in rights to co-develop and co-commercialize Verve programs. When Lilly acquired Verve, it also acquired these rights, effectively severing Beam's direct connection to the cardiovascular franchise.
The impact was double-edged. On one hand, the deal validated Beam's technology platform at a high level — a company built on Beam's base editing IP had been acquired for $1.3 billion by one of the world's largest pharma companies. This was powerful proof-of-concept for the entire base editing field. On the other hand, Beam lost its opt-in rights to what had been one of the most promising clinical-stage base editing programs in existence.
For Beam, the loss was partially offset by the Pfizer partnership, which provided substantial capital and validated the platform independently. But the strategic calculus had shifted. Beam was no longer the sole gatekeeper to base editing in cardiovascular disease. Lilly now controlled that territory directly.
The broader lesson for platform technology companies was clear: in a land-grab environment, the companies that control the clinical programs — not just the underlying technology — hold the strategic leverage. Licensing platform technology is valuable, but owning the therapeutic application is where the real value accrues in M&A.
What the CVR Tells Us About Risk
The CVR structure — $3.00 per share contingent on Phase 3 initiation within 10 years — deserves careful analysis, because it reveals how Lilly was thinking about the risk profile of the acquisition.
A 10-year window for Phase 3 initiation is unusually long. In most biotech acquisitions involving CVRs, the milestone is set 3-5 years out. Lilly's decision to extend the window to a decade suggests several things. First, it acknowledges that VERVE-102 is still in Phase 1b, meaning there is a full Phase 2 study and potentially years of dose-optimization work before a pivotal trial can begin. Second, it gives Lilly flexibility to pivot between targets — if VERVE-102 encounters problems, the ANGPTL3 program (VERVE-201) or entirely new programs developed using the acquired platform could satisfy the CVR milestone. Third, the long timeline may reflect regulatory uncertainty; gene editing for chronic diseases is a new regulatory paradigm, and the FDA's expectations for long-term safety data in cardiovascular patients are still being defined.
For Verve shareholders, the CVR represented a bet on Lilly's commitment to advancing the programs. At the time of the deal, the $3.00 CVR was trading at roughly $0.80-$1.20 in when-issued markets, suggesting that investors assigned a 25-40% probability of the milestone being achieved — a reasonable assessment given the early stage of development.
Comparing the Deal to Other Biotech M&A
The Lilly-Verve transaction is instructive when placed alongside other major gene editing and gene therapy M&A deals:
| Deal | Year | Value | Target Technology |
|---|---|---|---|
| AstraZeneca / Alexion | 2021 | $39B | Complement biology, rare disease |
| Pfizer / Seagen | 2023 | $43B | Antibody-drug conjugates, oncology |
| AbbVie / ImmunoGen | 2024 | $10.1B | ADCs, oncology |
| Vertex / Alpine Immune Sciences | 2024 | $4.9B | Engineered proteins, autoimmunity |
| Lilly / Verve | 2025 | $1.3B | Base editing, cardiovascular |
| Pfizer / Beam (partnership) | 2025 | $300M+ | Base editing, multi-target |
At $1.3 billion, the Lilly-Verve deal was modest compared to the mega-mergers that have defined recent pharma M&A. But several factors make it disproportionately significant. It was the first acquisition of a gene editing company by a top-5 pharma company. It targeted a disease area (cardiovascular) that affects hundreds of millions of patients globally, not a rare disease population. And it represented a bet on in vivo gene editing — therapy delivered directly into the patient's body — rather than the ex vivo approach used by first-generation gene editing therapies like Casgevy.
The relatively low price also reflected the risk. Verve had been through a clinical setback, its lead program had been deprioritized, and its most advanced remaining candidate was in early-stage trials. For Lilly, this was a calculated bet: buy the platform at a discount created by temporary adversity, then deploy the resources of a $800 billion company to push it through clinical development.
What This Means for the Gene Editing Industry
The Lilly-Verve acquisition carries several important implications for the gene editing sector as a whole.
Validation of in vivo editing. The first wave of approved gene editing therapies — Casgevy for sickle cell disease, investigational CAR-T programs — all use ex vivo approaches that require extracting cells, editing them in a laboratory, and returning them to the patient. In vivo editing, where the therapeutic is delivered directly into the body, has always been viewed as the more scalable and commercially viable approach, but it lacked clinical validation at scale. Verve's VERVE-102 data, and Lilly's willingness to pay $1.3 billion for it, provided the strongest validation yet that in vivo gene editing is clinically feasible and commercially attractive.
Expansion beyond rare diseases. Gene editing has been largely confined to rare disease applications — sickle cell disease, beta-thalassemia, certain genetic blood disorders. These are medically important but commercially limited markets. The Verve acquisition signaled that gene editing is ready to move into common chronic diseases that affect vast patient populations. Cardiovascular disease, with hundreds of millions of patients globally, represents a market orders of magnitude larger than anything gene editing has targeted before.
Pricing and reimbursement precedent. How Lilly prices a one-time cardiovascular gene editing therapy will set a precedent for the entire industry. Casgevy is priced at $2.2 million per patient, but it targets a rare disease affecting 100,000 Americans. A therapy for HeFH — which affects roughly 1.3 million Americans — cannot realistically carry the same price tag. The industry is watching closely to see whether Lilly adopts an outcomes-based pricing model, a subscription model, or something entirely new.
Manufacturing scalability. In vivo LNP-delivered therapies are inherently more scalable than ex vivo cell therapies. The manufacturing process for VERVE-102 is closer to mRNA vaccine production than to the bespoke, patient-specific manufacturing required for Casgevy. This scalability advantage was almost certainly part of Lilly's strategic calculus — a cardiovascular gene editing therapy that can be manufactured at scale and distributed through existing pharmaceutical supply chains is a fundamentally different commercial proposition than a cell therapy that must be made one patient at a time.
Expert Analysis: What Comes Next
The Lilly-Verve deal raises as many questions as it answers.
Can VERVE-102 survive a pivotal trial? The Phase 1b data was impressive, but Phase 1b studies are small, carefully controlled, and conducted in highly selected patient populations. The transition from early-stage to registration-enabling trials is where many gene editing programs have stumbled. Lilly will need to demonstrate not only sustained LDL reduction but also long-term safety — including the absence of off-target editing effects that might not manifest for years. The FDA's expectations for a therapy intended to be given once and remain active for a patient's lifetime are, by necessity, exceptionally high.
How will the FDA regulate one-time cardiovascular gene editing? There is no precedent for a one-time gene editing therapy in a chronic, common disease. The FDA approved Casgevy under its existing cell and gene therapy framework, but that framework was designed for rare diseases with small patient populations. A cardiovascular gene editing therapy targeting millions of patients will require new thinking about long-term follow-up requirements, post-marketing surveillance, and risk management. Lilly's regulatory strategy for VERVE-102 will be closely watched by every gene editing company in the industry.
Will competitors respond? Lilly's move will almost certainly accelerate competitive activity. Other pharma companies with cardiovascular franchises — Novartis (which sells Leqvio), Amgen (Repatha), and Regeneron (Praluent) — now face the prospect of a one-time therapy that could make their chronic treatments obsolete. Expect to see increased investment in gene editing partnerships and acquisitions across the industry.
What about ANGPTL3? Verve's ANGPTL3 program (VERVE-201) is earlier in development but could ultimately be even more significant. ANGPTL3 loss-of-function not only lowers LDL cholesterol but also reduces triglycerides and other atherogenic lipoproteins. A gene editing therapy targeting ANGPTL3 could address a broader range of dyslipidemia than PCSK9 editing alone. Lilly now owns this program as well, giving it optionality that extends well beyond the PCSK9 franchise.
The Bigger Picture
Step back from the specifics of the deal, and a larger narrative comes into focus. For decades, the pharmaceutical industry's business model has been built on chronic treatment — drugs that patients take daily, weekly, or monthly for the rest of their lives. This model generates predictable, recurring revenue and has made the industry enormously profitable. Gene editing, by its very nature, threatens to upend this model. A one-time treatment that cures a disease is antithetical to a business built on managing it.
The fact that Eli Lilly — a company that generates tens of billions of dollars per year from chronic therapies like Mounjaro, Zepbound, Humalog, and Verzenio — is investing in one-time genetic cures tells you something about where the industry believes it is heading. Lilly is not abandoning chronic treatment. But it is hedging, recognizing that the companies that own the cure will ultimately displace the companies that own the treatment.
The Verve acquisition is a $1.3 billion hedge on that future. And given the size of the cardiovascular disease market, it may turn out to be one of the most significant strategic bets in the history of the pharmaceutical industry.
References
[1] World Health Organization. "Cardiovascular Diseases (CVDs)." WHO Fact Sheet, June 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
[2] Centers for Disease Control and Prevention. "Heart Disease Facts." CDC, 2024. https://www.cdc.gov/heartdisease/facts.htm
[3] American Heart Association. "Cardiovascular Disease: A Costly Burden for America." AHA Policy Report, 2023. https://www.heart.org/en/about-us/policy-research
[4] Chowdhury R, et al. "Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences." European Heart Journal, 2013;34(38):2940-2948. https://doi.org/10.1093/eurheartj/eht295
[5] Cutler DM, Everett W. "Thinking outside the pillbox — medication adherence as a priority for health care reform." New England Journal of Medicine, 2010;362(17):1553-1555. https://doi.org/10.1056/NEJMp1002305
[6] Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease." New England Journal of Medicine, 2006;354(12):1264-1272. https://doi.org/10.1056/NEJMoa054013
[7] Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage." Nature, 2016;533(7603):420-424. https://doi.org/10.1038/nature17946
[8] Verve Therapeutics. "Verve Therapeutics Provides Update on Heart-1 Clinical Trial." Press Release, May 2024. https://www.vervetx.com/press-releases
[9] Verve Therapeutics. "Verve Therapeutics Announces Interim Data from Heart-2 Study of VERVE-102." Investor Presentation, 2025. https://www.vervetx.com/pipeline
[10] Eli Lilly and Company. "Lilly to Acquire Verve Therapeutics." Press Release, July 2025. https://investor.lilly.com/news-releases
[11] Pfizer Inc. "Pfizer and Beam Therapeutics Enter Strategic Collaboration for Base Editing Programs." Press Release, March 2025. https://www.pfizer.com/news
[12] Sanofi. "Sanofi Partners with Scribe Therapeutics to Advance Next-Generation Gene Editing." Press Release, 2025. https://www.sanofi.com/en/media-room/press-releases
